
样式: 排序: IF: - GO 导出 标记为已读
-
Albuminuria in cardiac ATTR amyloidosis: prevalence, progression and prognostic importance Eur. J. Heart Fail. (IF 18.2) Pub Date : 2023-11-23 Adam Ioannou, Muhammad U Rauf, Rishi K Patel, Yousuf Razvi, Aldostefano Porcari, Ana Martinez-Naharro, Lucia Venneri, Francesco Bandera, Ruta Virsinskaite, Tushar Kotecha, Dan Knight, Aviva Petrie, Carol Whelan, Ashutosh Wechalekar, Helen Lachmann, Philip N Hawkins, Scott D Solomon, Julian D Gillmore, Marianna Fontana
Transthyretin cardiac amyloidosis (ATTR-CA) is an infiltrative cardiomyopathy that commonly presents with concomitant chronic kidney disease. Albuminuria is common in heart failure and associated with worse outcomes, but its prevalence and relationship to outcome in ATTR-CA remains unclear.
-
Impact of vasodilators on diuretic response in patients with congestive heart failure: a mechanistic trial of cimlanod (BMS-986231) Eur. J. Heart Fail. (IF 18.2) Pub Date : 2023-11-21 Pierpaolo Pellicori, John G.F. Cleland, Maria Borentain, Jorg Taubel, Fraser Graham, Javed Khan, Dario Bruzzese, Paul Kessler, John J.V. McMurray, Adriaan A. Voors, Christopher M. O'Connor, John R. Teerlink, G. Michael Felker
Cimlanod is a nitroxyl donor with vasodilator properties.
-
Obesity in Heart Failure with Preserved Ejection Fraction: Insights from the REDUCE LAP-HF II Trial Eur. J. Heart Fail. (IF 18.2) Pub Date : 2023-11-21 Sheldon E. Litwin, Jan Komtebedde, Tim Seidler, Barry A. Borlaug, Sebastian Winkler, Scott D. Solomon, Jean-Christophe Eicher, Sula Mazimba, Rami Khawash, Aaron L. Sverdlov, Scott L. Hummel, Heiko Bugger, Florian Boenner, Elke Hoendermis, Maja Cikes, Catherine Demers, Guillherme Silva, Vanessa van Empel, Randall Starling, Martin Penicka, Donald E. Cutlip, Martin B. Leon, Dalane W. Kitzman, Dirk J.
Obesity is causally related to the development of HFpEF but complicates the diagnosis and treatment of this disorder. We aimed to determine the relationship between severity of obesity and clinical, echocardiographic and hemodynamic parameters in a large cohort of patients with documented HFpEF.
-
Rationale and design of the ESC Heart Failure III Registry – Implementation and discovery Eur. J. Heart Fail. (IF 18.2) Pub Date : 2023-11-21 Lars H. Lund, Maria Generosa Crespo-Leiro, Cecile Laroche, Jose M. Garcia-Pinilla, Ahmed Bennis, Eleonora B. Vataman, Marija Polovina, Slavica Radovanovic, Svetlana R. Apostolovic, Milika Ašanin, Andrzej Gackowski, Agnieszka Kaplon-Cieslicka, Irina Cabac-Pogorevici, Stefan D. Anker, Ovidiu Chioncel, Andrew J.S. Coats, Gerasimos Filippatos, Mitja Lainscak, Theresa Mcdonagh, Alexandre Mebazaa, Marco
Heart failure outcomes remain poor despite advances in therapy. The European Society of Cardiology Heart Failure III Registry (ESC HF III Registry) aims to characterize HF clinical features and outcomes and to assess implementation of guideline-recommended therapy in Europe and other ESC affiliated countries.
-
Association of Neighborhood-Level Material Deprivation with Adverse Outcomes and Processes of Care Among Patients with Heart Failure in a Single-Payer Healthcare System: A Population-Based Cohort Study Eur. J. Heart Fail. (IF 18.2) Pub Date : 2023-11-13 David Bobrowski, Andrew Dorovenis, Husam Abdel-Qadir, Candace D. McNaughton, Rea Alonzo, Jiming Fang, Peter C. Austin, Jacob A. Udell, Cynthia A. Jackevicius, David A. Alter, Clare L. Atzema, R. Sacha Bhatia, Gillian L. Booth, Andrew C.T. Ha, Sharon Johnston, Irfan Dhalla, Moira K. Kapral, Harlan M. Krumholz, Idan Roifman, Harindra C Wijeysundera, Dennis T. Ko, Karen Tu, Heather J. Ross, Michael J
We studied the association between neighborhood material deprivation, a metric estimating inability to attain basic material needs, with outcomes and processes of care among incident heart failure (HF) patients in a universal healthcare system.
-
Deep phenotyping of p.(V142I)-associated variant ATTR amyloid cardiomyopathy: distinct from wild-type ATTR amyloidosis? Eur. J. Heart Fail. (IF 18.2) Pub Date : 2023-11-13 Yousuf Razvi, Adam Ioannou, Rishi K Patel, Liza Chacko, Nina Karia, Mattia Riefolo, Aldostefano Porcari, Muhammad Umaid Rauf, Neasa Starr, Sashiananthan Ganesananthan, Iona Blakeney, Nandita Kaza, Stefano Filisetti, Roos Eline Bolhuis, Dorota Rowczenio, Janet Gilbertson, David Hutt, Shameem Mahmood, Helen J Lachmann, Ashutosh D Wechalekar, Tushar Kotecha, Daniel S Knight, John G Coghlan, Aviva Petrie
Transthyretin amyloid cardiomyopathy (ATTR-CM) is an increasingly recognised cause of heart failure. 3-4% of individuals of African descent carry a TTR gene mutation encoding the p.(V142I) variant, a powerful risk factor for development of variant ATTR-CM; this equates to 1.6 million carriers in the USA. We undertook deep phenotyping of p.(V142I)-ATTRv-CM and comparison with wild-type ATTR-CM (ATTRwt-CM)
-
Growth differentiation factor-15 and the effect of empagliflozin in heart failure: Findings from the EMPEROR program Eur. J. Heart Fail. (IF 18.2) Pub Date : 2023-11-14 João Pedro Ferreira, Milton Packer, Javed Butler, Gerasimos Filippatos, Stuart J. Pocock, James L. Januzzi, Naveed Sattar, Sandra González Maldonado, Marina Panova-Noeva, Mikhail Sumin, Serge Masson, Stefan D. Anker, Faiez Zannad
Growth differentiation factor-15 (GDF-15) is upregulated in part in response to cardiomyocyte stretch and stress, and it exerts a protective role that is mediated by its action to suppress signalling through insulin-like growth factor (IGF) and enhance signalling through adenosine monophosphate-activated protein kinase (AMPK). Sodium–glucose cotransporter 2 (SGLT2) inhibitors improve outcomes in heart
-
Proteomic prediction of incident heart failure and its main subtypes Eur. J. Heart Fail. (IF 18.2) Pub Date : 2023-11-08 Valur Emilsson, Brynjolfur G Jonsson, Thomas R Austin, Valborg Gudmundsdottir, Gisli T Axelsson, Elisabet A Frick, Thorarinn Jonmundsson, Anna E Steindorsdottir, Joseph Loureiro, Jennifer A Brody, Thor Aspelund, Lenore J Launer, Gudmundur Thorgeirsson, Kirsten A Kortekaas, Jan H Lindeman, Anthony P Orth, John R Lamb, Bruce M Psaty, Jorge R Kizer, Lori L Jennings, Vilmundur Gudnason
To examine the ability of serum proteins in predicting future heart failure (HF) events, including HF with reduced or preserved ejection fraction (HFrEF or HFpEF), in relation to event time, and with or without considering established HF-associated clinical variables.
-
Neuropeptide Y is elevated in heart failure and is an independent predictor of outcomes Eur. J. Heart Fail. (IF 18.2) Pub Date : 2023-11-08 Kirsty McDowell, Carly Adamson, Colette Jackson, Ross Campbell, Paul Welsh, Mark C. Petrie, John J.V. McMurray, Pardeep S Jhund, Neil Herring
Neuropeptide Y (NPY) is the most abundant neuropeptide found in the heart and is released alongside norepinephrine following prolonged sympathetic activation, a process that is implicated in the pathophysiology of heart failure (HF). In patients with severely impaired left ventricular ejection fraction (LVEF) undergoing cardiac resynchronization therapy (CRT), higher levels of NPY measured in coronary
-
What about current recommendations for extracorporeal life support in acute myocardial infarction-associated cardiogenic shock: Stay or go? or time to revise? Eur. J. Heart Fail. (IF 18.2) Pub Date : 2023-11-08 Clément Delmas, Christophe Vandenbriele, Federico Pappalardo, François Roubille
Extracorporeal life support (ECLS) has gained increasing utilization in the management of cardiogenic shock related to acute myocardial infarction (AMI-CS). The evidence primarily stems from observational studies originating from prominent European expert centres. Despite these studies reporting high 30-day mortality rates (up to 50%) and substantial complication rates (up to 50% severe adverse events)
-
Clinical presentation, shock severity and mortality in patients with de novo versus acute-on-chronic heart failure-related cardiogenic shock Eur. J. Heart Fail. (IF 18.2) Pub Date : 2023-11-08 Jonas Sundermeyer, Caroline Kellner, Benedikt N. Beer, Lisa Besch, Angela Dettling, Letizia Fausta Bertoldi, Stefan Blankenberg, Jeroen Dauw, Zouhir Dindane, Dennis Eckner, Ingo Eitel, Tobias Graf, Patrick Horn, Joanna Jozwiak-Nozdrzykowska, Paulus Kirchhof, Stefan Kluge, Axel Linke, Ulf Landmesser, Peter Luedike, Enzo Lüsebrink, Nicolas Majunke, Norman Mangner, Octavian Maniuc, Sven Möbius Winkler
-
Guideline-directed medical therapy in severe heart failure with reduced ejection fraction: an analysis from the HELP-HF registry Eur. J. Heart Fail. (IF 18.2) Pub Date : 2023-11-07 Daniela Tomasoni, Matteo Pagnesi, Giada Colombo, Mauro Chiarito, Davide Stolfo, Luca Baldetti, Carlo Mario Lombardi, Marianna Adamo, Giuseppe Maggi, Riccardo Maria Inciardi, Ferdinando Loiacono, Marta Maccallini, Alessandro Villaschi, Gaia Gasparini, Marco Montella, Stefano Contessi, Daniele Cocianni, Maria Perotto, Giuseppe Barone, Marco Merlo, Alberto Maria Cappelletti, Giuseppe Rosano, Gianfranco
-
Sacubitril/valsartan compared to ramipril in high-risk post-myocardial infarction patients stratified according to use of mineralocorticoid receptor antagonists: insight from the PARADISE MI trial Eur. J. Heart Fail. (IF 18.2) Pub Date : 2023-11-06 Morten Schou, Brian Claggett, Zi Michael Miao, Alberto Fernandez, Gerasimos Filippatos, Christopher Granger, Karola Jering, Aldo P. Maggioni, Finnian McCausland, Julio Nuñez Villota, Jean-Lucien Rouleau, Freny Vaghaiwalla Mody, Peter van der Meer, Dragos Vinereanu, Martina McGrath, Yinong Zhou, Douglas L. Mann, Scott D. Solomon, Philippe Gabriel Steg, Eugene Braunwald, John J.V. McMurray, Marc A. Pfeffer
-
Interaction of Heart Failure and Stroke: A clinical consensus statement of the ESC Council on Stroke, the Heart Failure Association (HFA) and the ESC Working Group on Thrombosis Eur. J. Heart Fail. (IF 18.2) Pub Date : 2023-10-31 Wolfram Doehner, Michael Böhm, Giuseppe Boriani, Christina Christersson, Andrew JS Coats, Karl Georg Haeusler, Ian D Jones, Gregory Y.H. Lip, Marco Metra, George Ntaios, Gianluigi Savarese, Eduard Shantsila, Gemma Vilahur, Giuseppe Rosano
Heart failure (HF) is a major disease in our society that often presents with multiple comorbidities with mutual interaction and aggravation. The comorbidity of HF and stroke is a high risk condition that requires particular attention to ensure early detection of complications, efficient diagnostic workup, close monitoring, and consequent treatment of the patient. The bi-directional interaction between
-
The utilization and impact of cardiovascular specialists on guideline-directed medical scores: An analysis of a diverse, multi-state, electronic health record-based registry. Eur. J. Heart Fail. (IF 18.2) Pub Date : 2023-10-31 Trejeeve Martyn,Joshua Saef,Umesh N Khot,Kathryn A Martinez,Todd J Brophy,Lucianne West,Cari Cristiani,Hunter Block-Beach,Jessica A Hohman,Tim Sobol,Jeremy A Brooksbank,Michael B Surratt,Christopher Babiuch,Samir R Kapadia,W H Wilson Tang,Jerry D Estep,Randall C Starling
-
Long-term outcome after upgrade to cardiac resynchronization therapy: A propensity score-matched analysis Eur. J. Heart Fail. (IF 18.2) Pub Date : 2023-10-31 Sander Trenson, Gabor Voros, Pieter Martens, Sebastian Ingelaere, Pascal Betschart, Jens-Uwe Voigt, Matthias Dupont, Alexander Breitenstein, Jan Steffel, Rik Willems, Frank Ruschitzka, Wilfried Mullens, Stephan Winnik, Bert Vandenberk
Cardiac resynchronization therapy (CRT) is a cornerstone in the management of chronic heart failure in patients with a broad or paced QRS. However, data on long-term outcome after upgrade to CRT are scarce.
-
Characteristics and outcomes of patients with atrial versus ventricular secondary tricuspid regurgitation undergoing tricuspid transcatheter edge-to-edge repair – Results from the TriValve registry Eur. J. Heart Fail. (IF 18.2) Pub Date : 2023-10-31 Giulio Russo, Luigi P Badano, Marianna Adamo, Hannes Alessandrini, Martin Andreas, Daniel Braun, Kim A. Connelly, Paolo Denti, Rodrigo Estevez-Loureiro, Neil Fam, Mara Gavazzoni, Rebecca T. Hahn, Claudia Harr, Joerg Hausleiter, Dominique Himbert, Daniel Kalbacher, Edwin Ho, Azeem Latib, Edith Lubos, Sebastian Ludwig, Philipp Lurz, Vanessa Monivas, Georg Nickenig, Daniela Pedicino, Giovanni Pedrazzini
Functional or secondary tricuspid regurgitation (STR) is the most common phenotype of tricuspid regurgitation (TR) with atrial STR (ASTR) and ventricular STR (VSTR) being recently identified as two distinct entities. Data on tricuspid transcatheter edge-to-edge repair (T-TEER) in patients with STR according to phenotype (i.e. ASTR vs. VSTR) are lacking. The aim of this study was to assess characteristics
-
Early changes in renal function during rapid up-titration of guideline-directed medical therapy following an admission for acute heart failure Eur. J. Heart Fail. (IF 18.2) Pub Date : 2023-10-31 Jozine M. ter Maaten, Alexandre Mebazaa, Beth Davison, Christopher Edwards, Marianna Adamo, Mattia Arrigo, Marianela Barros, Jan Biegus, Jelena Čelutkienė, Kamilė Čerlinskaitė-Bajorė, Ovidiu Chioncel, Alain Cohen-Solal, Albertino Damasceno, Rafael Diaz, Gerasimos Filippatos, Etienne Gayat, Antoine Kimmoun, Carolyn S.P. Lam, Valentine Leopold, Maria Novosadova, Matteo Pagnesi, Peter S. Pang, Piotr Ponikowski
In this subgroup analysis of STRONG-HF, we explored the association between changes in renal function and efficacy of rapid up-titration of guideline-directed medical therapy (GDMT) according to a high-intensity care (HIC) strategy.
-
Incidence, risk assessment and prevention of sudden cardiac death in cardiomyopathies Eur. J. Heart Fail. (IF 18.2) Pub Date : 2023-10-31 Marija Polovina, Carsten Tschöpe, Giuseppe Rosano, Marco Metra, Filippo Crea, Wilfried Mullens, Johann Bauersachs, Karen Sliwa, Rudolf A. de Boer, Dimitrios Farmakis, Thomas Thum, Domenico Corrado, Antoni Bayes-Genis, Biykem Bozkurt, Gerasimos Filippatos, Andre Keren, Hadi Skouri, Brenda Moura, Maurizio Volterrani, Magdy Abdelhamid, Milika Ašanin, Gordana Krljanac, Milenko Tomić, Gianluigi Savarese
-
Short-term effects of sacubitril/valsartan therapy on myocardial oxygen consumption and energetic efficiency of cardiac work in heart failure with reduced ejection fraction: A randomized controlled study Eur. J. Heart Fail. (IF 18.2) Pub Date : 2023-10-31 Sergey V. Nesterov, Johanna Räty, Wail Nammas, Teemu Maaniitty, Xavier Galloo, Jan Stassen, Sanna Laurila, Tuija Vasankari, Jenni Huusko, Jeroen J. Bax, Antti Saraste, Juhani Knuuti
-
Hypotension in heart failure is less harmful if associated with high or increasing doses of heart failure medication: Insights from the Swedish Heart Failure Registry Eur. J. Heart Fail. (IF 18.2) Pub Date : 2023-10-26 Nicolas Girerd, Stefano Coiro, Lina Benson, Gianluigi Savarese, Ulf Dahlström, Patrick Rossignol, Lars H. Lund
-
Predictors of outcome in a contemporary cardiac sarcoidosis population: Role of brain natriuretic peptide, left ventricular function and myocardial inflammation Eur. J. Heart Fail. (IF 18.2) Pub Date : 2023-10-25 Vasileios Kouranos, Rajdeep S. Khattar, Joseph Okafor, Raheel Ahmed, Alessia Azzu, John Arun Baksi, Kshama Wechalekar, Martin R. Cowie, Athol Umfrey Wells, Thomas F. Lüscher, Rakesh Sharma
-
Qiliqiangxin: A multifaceted holistic treatment for heart failure or a pharmacological probe for the identification of cardioprotective mechanisms? Eur. J. Heart Fail. (IF 18.2) Pub Date : 2023-10-25 Milton Packer
The active ingredients in many traditional Chinese medicines are isoprene oligomers with a diterpenoid or triterpenoid structure, which exert cardiovascular effects by signalling through nutrient surplus and nutrient deprivation pathways. Qiliqiangxin (QLQX) is a commercial formulation of 11 different plant ingredients, whose active compounds include astragaloside IV, tanshione IIA, ginsenosides (Rb1
-
Comprehensive vasodilatation in women with acute heart failure: Novel insights from the GALACTIC randomized controlled trial Eur. J. Heart Fail. (IF 18.2) Pub Date : 2023-10-23 Desiree Wussler, Maria Belkin, Micha T. Maeder, Joan Walter, Samyut Shrestha, Karolina Kupska, Michelle Stierli, Dayana Flores, Nikola Kozhuharov, Danielle Menosi Gualandro, Mucio Tavares de Oliveira Junior, Zaid Sabti, Markus Noveanu, Thenral Socrates, Antoni Bayés-Genis, Alessandro Sionis, Patrick Simon, Eleni Michou, Samuel Gujer, Tommaso Gori, Philip Wenzel, Otmar Pfister, Nisha Arenja, Richard
-
Epicardial adipose tissue and cardiac dysfunction: Progress in knowledge but questions remain. Eur. J. Heart Fail. (IF 18.2) Pub Date : 2023-10-19 Michelle Lobeek,Michiel Rienstra,Thomas M Gorter
-
Exercise-based cardiac rehabilitation for adults with heart failure – 2023 Cochrane systematic review and meta-analysis Eur. J. Heart Fail. (IF 18.2) Pub Date : 2023-10-18 Cal D. Molloy, Linda Long, Ify R. Mordi, Charlene Bridges, Viral A. Sagar, Edward J. Davies, Andrew J.S. Coats, Hasnain Dalal, Karen Rees, Sally J. Singh, Rod S. Taylor
-
Sodium-glucose cotransporter 2 inhibitors on top of intravenous iron in patients with heart failure and iron deficiency: Any incremental effect? Eur. J. Heart Fail. (IF 18.2) Pub Date : 2023-10-17 Gianluigi Savarese,Javed Butler,Piotr Ponikowki,Stefan D Anker
-
Overcoming vulnerability in heart failure: Transitional tactical toughness. Eur. J. Heart Fail. (IF 18.2) Pub Date : 2023-10-12 Francesco Castagna,Panagiotis Simitsis,Mandeep R Mehra
-
Reply to 'Aortic regurgitation for adverse cardiovascular events: Really harmless or just hidden?' Eur. J. Heart Fail. (IF 18.2) Pub Date : 2023-10-12 Angiza Shahim,Bahira Shahim,Lars H Lund
-
Aortic stenosis and heart failure with preserved ejection fraction: A shared phenotypic puzzle. Eur. J. Heart Fail. (IF 18.2) Pub Date : 2023-10-12 Andrea Scotti,Leandro Slipczuk,Azeem Latib
-
A machine learning-derived risk score predicts mortality in East Asian patients with acute heart failure. Eur. J. Heart Fail. (IF 18.2) Pub Date : 2023-10-12 Jin Joo Park,Se Yong Jang,Eric Adler,Faraz Ahmad,Claudio Campagnari,Avi Yagil,Barry Greenberg
-
Heart Failure-Cardiogenic Shock: A Need for Time-Dependent Quality Indicators. Eur. J. Heart Fail. (IF 18.2) Pub Date : 2023-10-12 Nuccia Morici,Federico Pappalardo
-
Persistent high mortality in AMI-associated cardiogenic shock despite early mechanical circulatory support: Need for stepwise and integrated approach of care. Eur. J. Heart Fail. (IF 18.2) Pub Date : 2023-10-12 Clément Delmas,Christophe Vandenbriele,Federico Pappalardo
-
Contemporary use of temporary mechanical circulatory support in infarct-related cardiogenic shock: Time to stop and reflect? Eur. J. Heart Fail. (IF 18.2) Pub Date : 2023-10-12 Jacob Eifer Møller,Jesper Kjaergaard,Christian Hassager
-
Clinical characteristics and prognosis of patients with isolated cardiac sarcoidosis: Insights from the ILLUMINATE-CS study Eur. J. Heart Fail. (IF 18.2) Pub Date : 2023-10-12 Daichi Maeda, Yuya Matsue, Taishi Dotare, Tsutomu Sunayama, Takashi Iso, Kenji Yoshioka, Takeru Nabeta, Yoshihisa Naruse, Takeshi Kitai, Tatsunori Taniguchi, Hidekazu Tanaka, Takahiro Okumura, Yuichi Baba, Tohru Minamino
-
Outcomes at 1 year in women with peripartum cardiomyopathy: Findings from the ESC EORP PPCM Registry Eur. J. Heart Fail. (IF 18.2) Pub Date : 2023-10-12 Alice M. Jackson, Johann Bauersachs, Mark C. Petrie, Peter van der Meer, Cecile Laroche, Hasan Ali Farhan, Alexandra Frogoudaki, Bassem Ibrahim, Doaa A. Fouad, Albertino Damasceno, Kamilu Karaye, Sorel Goland, Aldo P. Maggioni, Olivia Briton, Karen Sliwa
There are few prospective reports of 1-year outcomes for women with peripartum cardiomyopathy (PPCM). We report findings from the European Society of Cardiology EURObservational Research Programme PPCM Registry.
-
The different risk of new-onset, chronic, worsening, and advanced heart failure: A systematic review and meta-regression analysis Eur. J. Heart Fail. (IF 18.2) Pub Date : 2023-10-12 Abdul Shakoor, Sabrina Abou Kamar, Jishnu Malgie, Isabella Kardys, Jeroen Schaap, Rudolf A. de Boer, Nicolas M. van Mieghem, Robert M.A. van der Boon, Jasper J. Brugts
-
Safety of continuing mineralocorticoid receptor antagonist treatment in patients with heart failure with reduced ejection fraction and severe kidney disease: data from Swedish Heart Failure Registry Eur. J. Heart Fail. (IF 18.2) Pub Date : 2023-10-05 Federica Guidetti, Lars H. Lund, Lina Benson, Camilla Hage, Francesca Musella, Davide Stolfo, Peter G.M. Mol, Andreas J. Flammer, Frank Ruschitzka, Ulf Dahlstrom, Giuseppe M.C. Rosano, Oscar Ö. Braun, Gianluigi Savarese
-
Tafamidis in patients with severe heart failure due to transthyretin amyloidosis cardiomyopathy: improved long-term survival. Eur. J. Heart Fail. (IF 18.2) Pub Date : 2023-10-04 Alwin Tubben,Hans L A Nienhuis,Peter van der Meer
-
Personalizing anti-inflammatory therapy in heart failure: a new way. Eur. J. Heart Fail. (IF 18.2) Pub Date : 2023-10-04 Domingo Pascual-Figal,Jose Javier Fuster,Antoni Bayes-Genis
-
Striving for the "Perfect" Definition of Iron Deficiency in Heart Failure. Eur. J. Heart Fail. (IF 18.2) Pub Date : 2023-10-04 Jan Biegus,Piotr Ponikowski
-
October 2023 at a glance: From prevention to diagnosis, prognosis and treatment of acute decompensation and comorbidities. Eur. J. Heart Fail. (IF 18.2) Pub Date : 2023-10-01 Daniela Tomasoni,Marianna Adamo,Marco Metra
-
Watchful waiting for venting in venoarterial extracorporeal membrane oxygenation. Eur. J. Heart Fail. (IF 18.2) Pub Date : 2023-09-28 Julie K K Vishram-Nielsen,Finn Gustafsson
-
Reply to 'Phenotypic characterization of heart failure with preserved ejection fraction'. Eur. J. Heart Fail. (IF 18.2) Pub Date : 2023-09-28 Yuki Saito,Masaru Obokata
-
Sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction and chronic obstructive pulmonary disease - No heterogeneity. Eur. J. Heart Fail. (IF 18.2) Pub Date : 2023-09-28 Camilla Hage,Lars H Lund
-
Reply to 'Effects of tafamidis on heart failure hospitalization: The tale of the dog that did not bark. Eur. J. Heart Fail. (IF 18.2) Pub Date : 2023-09-28 Perry Elliott,Balarama Gundapaneni,Pablo Garcia-Pavia
-
Impact of COVID-19 in patients with heart failure with mildly reduced or preserved ejection fraction enrolled in the DELIVER trial Eur. J. Heart Fail. (IF 18.2) Pub Date : 2023-09-28 Ankeet S. Bhatt, Mikhail N. Kosiborod, Brian L. Claggett, Zi Michael Miao, Muthiah Vaduganathan, Carolyn S.P. Lam, Adrian F. Hernandez, Felipe A. Martinez, Silvio E. Inzucchi, Sanjiv J. Shah, Rudolf A. de Boer, Pardeep S. Jhund, Akshay S. Desai, James C. Fang, Yaling Han, Josep Comin-Colet, Jarosław Drożdż, Orly Vardeny, Bela Merkely, Daniel Lindholm, Magnus Peterson, Anna Maria Langkilde, John J.V
-
Calcium channel blocker use and outcomes in patients with heart failure and mildly reduced and preserved ejection fraction Eur. J. Heart Fail. (IF 18.2) Pub Date : 2023-09-28 Shingo Matsumoto, Toru Kondo, Mingming Yang, Ross T. Campbell, Kieran F. Docherty, Rudolf A. de Boer, Akshay S. Desai, Carolyn S.P. Lam, Milton Packer, Bertram Pitt, Jean L. Rouleau, Muthiah Vaduganathan, Faiez Zannad, Michael R. Zile, Scott D. Solomon, Pardeep S. Jhund, John J.V. McMurray
Patients with heart failure (HF) and mildly reduced ejection fraction (HFmrEF) and preserved ejection fraction (HFpEF) are often treated with calcium channel blockers (CCBs), although the safety of CCBs in these patients is uncertain. We aimed to investigate the association between CCB use and clinical outcomes in patients with HFmrEF/HFpEF; CCBs were examined overall, as well as by subtype (dihydropyridine
-
From prediction to prevention: The role of heart failure risk models: Heart to Heart: The Promise and Pitfalls of Heart Failure Risk Prediction Models. Eur. J. Heart Fail. (IF 18.2) Pub Date : 2023-09-26 Matthew W Segar,Neil Keshvani,Ambarish Pandey
-
Using combinational diuretics across the spectrum of renal function. Eur. J. Heart Fail. (IF 18.2) Pub Date : 2023-09-26 Pieter Martens,Wilfried Mullens
-
Provocative testing in the evaluation of heart failure with preserved ejection fraction: Not all stresses are created equal. Eur. J. Heart Fail. (IF 18.2) Pub Date : 2023-09-21 Yogesh N V Reddy,Barry A Borlaug
-
Venting strategies for extracorporeal membrane oxygenation patients: More questions than answers but a plea for more clinical trials on the topic! Eur. J. Heart Fail. (IF 18.2) Pub Date : 2023-09-20 Clément Delmas,Aurore Ughetto,Guillaume Lebreton,François Roubille
-
Phenotype, outcomes and natural history of early-stage non-ischaemic cardiomyopathy Eur. J. Heart Fail. (IF 18.2) Pub Date : 2023-09-20 Daniel J. Hammersley, Richard E. Jones, Ruth Owen, Lukas Mach, Amrit S. Lota, Zohya Khalique, Antonio De Marvao, Emmanuel Androulakis, Suzan Hatipoglu, Ankur Gulati, Rohin K. Reddy, Won Young Yoon, Suprateeka Talukder, Riya Shah, Resham Baruah, Kaushik Guha, Antonis Pantazis, A. John Baksi, John Gregson, John G.F. Cleland, Upasana Tayal, Dudley J. Pennell, James S. Ware, Brian P. Halliday, Sanjay K
-
Non-cardiac comorbidities and intensive up-titration of oral treatment in patients recently hospitalized for heart failure: Insights from the STRONG-HF trial Eur. J. Heart Fail. (IF 18.2) Pub Date : 2023-09-20 Ovidiu Chioncel, Beth Davison, Marianna Adamo, Laura E. Antohi, Mattia Arrigo, Marianela Barros, Jan Biegus, Kamilė Čerlinskaitė-Bajorė, Jelena Celutkiene, Alain Cohen-Solal, Albertino Damasceno, Rafael Diaz, Christopher Edwards, Gerasimos Filippatos, Antoine Kimmoun, Carolyn S.P. Lam, Marco Metra, Maria Novosadova, Matteo Pagnesi, Peter S. Pang, Piotr Ponikowski, Razvan I. Radu, Hadiza Saidu, Karen
-
Practical algorithms for early diagnosis of heart failure and heart stress using NT-proBNP: A clinical consensus statement from the Heart Failure Association of the ESC Eur. J. Heart Fail. (IF 18.2) Pub Date : 2023-09-15 Antoni Bayes-Genis, Kieran F. Docherty, Mark C. Petrie, James L. Januzzi, Christian Mueller, Lisa Andreson, Biykem Bozkurt, Javed Butler, Ovidiu Chioncel, John G.F. Cleland, Ruxandra Christodorescu, Stefano Del Prato, Finn Gustafsson, Carolyn S.P. Lam, Brenda Moura, Rodica Pop-Busui, Petar Seferovic, Maurizio Volterrani, Muthiah Vaduganathan, Marco Metra, Giuseppe Rosano
Diagnosing heart failure is often difficult due to the non-specific nature of symptoms, which can be caused by a range of medical conditions. Natriuretic peptides (NPs) have been recognized as important biomarkers for diagnosing heart failure. This document from the Heart Failure Association examines the practical uses of N-terminal pro-B-type natriuretic peptide (NT-proBNP) in various clinical scenarios
-
Knowledge is power, can it be leveraged to improve heart failure care? Eur. J. Heart Fail. (IF 18.2) Pub Date : 2023-09-14 Charles F Sherrod,Nobuhiro Ikemura,John A Spertus
-
Myocardial injury related to SARS-CoV-2 mRNA vaccination: The plot thickens. Eur. J. Heart Fail. (IF 18.2) Pub Date : 2023-09-14 Nir Levi,Tal Hasin
-
When and how? Two simple questions to determine cancer status and inform therapeutic decisions and trial design in heart failure Eur. J. Heart Fail. (IF 18.2) Pub Date : 2023-09-13 Pietro Ameri, Muthiah Vaduganathan
This article refers to ‘Patient mortality following new-onset heart failure stratified by cancer type and status’ by N. Nouhravesh et al., published in this issue on pages 1857–1865. Large observational studies indicate that as many as 15–25% of patients with heart failure (HF) have a history of cancer,1, 2 and many may have more active cancers requiring ongoing oncological care. For instance, in the
-
Supervised exercise training in patients with advanced heart failure and left ventricular assist device: A multicentre randomized controlled trial (Ex-VAD trial) Eur. J. Heart Fail. (IF 18.2) Pub Date : 2023-09-13 Anna Feuerstein, Felix Schoenrath, Evgeny Belyavskiy, Jan Knierim, Tim Friede, Marius Placzek, Doris Bach, Elisabeth Pieske-Kraigher, Christoph Herrmann-Lingen, Ralf Westenfeld, Michael Roden, Meike Rybczynski, Nicolas Verheyen, Marcus Dörr, Stephan von Haehling, Stefan Störk, Martin Halle, Volkmar Falk, Burkert Pieske, Frank Edelmann
-
Heart failure patients with improved ejection fraction: Insights from the MECKI score database Eur. J. Heart Fail. (IF 18.2) Pub Date : 2023-09-13 Piergiuseppe Agostoni, Francesca Romana Pluchinotta, Elisabetta Salvioni, Massimo Mapelli, Arianna Galotta, Alice Bonomi, Damiano Magrì, Enrico Perna, Stefania Paolillo, Ugo Corrà, Rosa Raimondo, Rocco Lagioia, Roberto Badagliacca, Pasquale Perrone Filardi, Anna Apostolo, Michele Senni, Annamaria Iorio, Michele Correale, Jeness Campodonico, Pietro Palermo, Mariantonietta Cicoira, Marco Metra, Marco